{
  "total_samples": 1519,
  "topics": {
    "cystic fibrosis": 45,
    "COVID-19 clinical predictors": 2,
    "COVID-19 immunity": 2,
    "Epilepsy": 51,
    "Drug development/Phase III trials (Oncology/Urology)": 1,
    "ALS": 45,
    "Drug development/Phase III trials (Oncology/Breast)": 6,
    "COVID-19 correlates of protection": 1,
    "COVID-19 vaccines": 3,
    "Drug development/Phase III trials (Oncology/GI)": 4,
    "Long COVID": 5,
    "Alzheimer's disease": 51,
    "Drug development/Phase III trials (Hematology/Oncology)": 6,
    "Huntington's disease": 36,
    "COVID-19 pathogenesis": 1,
    "Drug development/Phase III trials (Oncology/Lung)": 3,
    "COVID-19 complications": 2,
    "COVID-19 critical care": 1,
    "COVID-19 pathophysiology": 1,
    "Drug development/Phase III trials (Infectious disease/Hepatology)": 2,
    "Drug development/Phase III trials (Infectious disease/Mycology)": 1,
    "Drug development/Phase III trials (Infectious disease)": 3,
    "COVID-19 respiratory support": 1,
    "COVID-19 immunology": 2,
    "Parkinson's disease": 52,
    "Drug development/Phase III trials (Gastroenterology/IBD safety)": 1,
    "COVID-19 variants": 1,
    "Drug interactions within trials (Rheumatology/Immunogenicity)": 1,
    "Drug development/Phase III trials (Infectious disease/Urology)": 1,
    "COVID-19 prevention": 3,
    "Drug interactions/Clinical pharmacology (Oncology)": 2,
    "COVID-19 vaccine safety": 1,
    "COVID-19 in pregnancy": 1,
    "Drug interactions/Clinical pharmacology (Immunology)": 1,
    "Drug interactions within trials (Psychiatry/General medicine)": 1,
    "Drug interactions/Clinical pharmacology (Women’s health)": 1,
    "Clinical trials/Safety and management (Immunology/Oncology)": 1,
    "Clinical trials/Prognosis and dosing (Cardiology/Nephrology)": 1,
    "COVID-19 therapeutics": 3,
    "Clinical trials/Supportive care (Oncology)": 1,
    "Drug interactions within trials (Cardiology)": 1,
    "COVID-19 sequelae": 1,
    "COVID-19 thrombosis management": 1,
    "Drug interactions/Clinical pharmacology (Endocrinology)": 2,
    "Rheumatoid arthritis": 41,
    "COVID-19 antiviral resistance": 2,
    "Drug interactions/Safety (Pain medicine)": 1,
    "Drug interactions within trials (Neurology/Headache)": 1,
    "Drug development/Phase III trials (Psychiatry/Safety)": 1,
    "HIV antiretroviral therapy": 4,
    "Drug interactions/Clinical pharmacology (Infectious disease)": 2,
    "HIV cure research": 1,
    "Clinical trials/Prognosis and dosing (Oncology)": 1,
    "Drug development/Clinical pharmacology (Dose optimization)": 1,
    "Drug development/Phase III trials (Vaccines/Interactions)": 1,
    "HIV prevention": 2,
    "Drug development/Phase III trials (Bone health)": 1,
    "HIV treatment outcomes": 1,
    "Drug development/Phase III trials (Pulmonology/Strategy)": 1,
    "HIV drug resistance": 2,
    "Drug development/Clinical trials (IBD/Personalized dosing)": 1,
    "HIV comorbidities": 2,
    "Drug development/Phase III trials (Infectious disease/Oncology supportive care)": 1,
    "Drug development/Phase III trials (Neurology)": 1,
    "HIV opportunistic infection prevention": 1,
    "HIV/TB coinfection": 1,
    "HIV opportunistic infections": 1,
    "Drug interactions within trials (Geriatrics/Urology)": 1,
    "Clinical trials/Prognosis and safety modifiers (Bone health)": 1,
    "Clinical trials/Safety comparison (Oncology)": 1,
    "HIV in pregnancy": 1,
    "Drug interactions within trials (Oncology/Hematology)": 1,
    "HIV opportunistic infection treatment": 1,
    "HIV diagnosis strategies": 2,
    "HIV prevention and control": 1,
    "Drug development/Phase III trials (Cardiology/HFpEF)": 1,
    "Drug interactions within trials (Nephrology)": 1,
    "HIV neuropathogenesis": 1,
    "HIV virology": 1,
    "Drug interactions/Clinical pharmacology (Transplant medicine)": 1,
    "Drug development/Phase III trials (Lipidology)": 2,
    "Drug development/Phase III trials (Transplant medicine)": 1,
    "Drug development/Phase III trials (Gastroenterology/Drug safety)": 1,
    "HIV treatment monitoring": 1,
    "Drug development/Clinical trials (Hematology/Nutrition)": 1,
    "Drug interactions within trials (Endocrinology)": 1,
    "Systemic lupus erythematosus": 44,
    "HIV immunotherapy": 1,
    "Drug development/Phase III trials (Cardiology)": 1,
    "HIV viral hepatitis coinfection": 1,
    "Drug development/Phase III trials (Infectious disease/Gastroenterology)": 2,
    "HIV/HCV coinfection": 1,
    "HIV-associated malignancy risk": 1,
    "Drug interactions/Clinical trials (Neurology/Women’s health)": 1,
    "Drug interactions/Clinical pharmacology (Rheumatology/Infectious disease)": 1,
    "HIV-associated malignancies": 1,
    "HIV care delivery": 3,
    "Drug development/Phase III trials (Sleep medicine)": 1,
    "Drug development/Clinical trials (Hepatology/Strategy)": 1,
    "HIV prevention and public health": 1,
    "Drug development/Phase III trials (Rheumatology)": 3,
    "HIV ART metabolic effects": 1,
    "HIV cardiovascular disease": 1,
    "Drug development/Phase III trials (Oncology/Hematology)": 1,
    "HIV treatment timing": 1,
    "Clinical trials/Design and concomitant meds (IBD)": 1,
    "NSCLC EGFR targeted therapy": 1,
    "Pediatric HIV treatment": 1,
    "NSCLC immunotherapy vs chemotherapy": 1,
    "HIV vertical transmission": 1,
    "HIV pharmacology": 1,
    "HIV prognosis": 2,
    "NSCLC ALK targeted therapy": 1,
    "HIV and COVID-19 immunity": 1,
    "NSCLC EGFR resistance mechanisms": 1,
    "Antibiotic-resistant bacterial infections": 2,
    "TNBC neoadjuvant immunotherapy": 1,
    "Breast cancer HER2 therapy": 1,
    "Carbapenem-resistant infections": 4,
    "Ovarian cancer PARP therapy": 1,
    "Ovarian cancer maintenance therapy": 1,
    "Breast cancer predictive biomarkers": 1,
    "Ovarian cancer combination immunotherapy": 1,
    "Colorectal cancer targeted therapy selection": 1,
    "Multidrug-resistant Gram-negative infections": 1,
    "Antibiotic resistance mechanisms": 1,
    "Colorectal cancer immunotherapy resistance": 1,
    "Melanoma targeted vs immunotherapy": 1,
    "AMR and COVID-19": 1,
    "Melanoma resistance mechanisms": 1,
    "Renal cell carcinoma immunotherapy combinations": 1,
    "AMR epidemiology": 4,
    "AMR diagnostics and stewardship": 1,
    "Immunotherapy adverse outcomes predictors": 1,
    "Multiple sclerosis": 41,
    "Antifungal-resistant infections": 2,
    "Hepatocellular carcinoma systemic therapy": 1,
    "HCC immunotherapy resistance biology": 1,
    "Gastric cancer chemo-immunotherapy biomarkers": 1,
    "ESBL infections": 3,
    "AMR infection prevention": 6,
    "Gastric cancer targeted therapy biomarkers": 1,
    "Esophageal cancer combined modality immunotherapy": 1,
    "Antibiotic pharmacodynamics": 1,
    "Chemo-immunotherapy mechanistic synergy": 1,
    "Antibiotic-associated infections": 2,
    "Pancreatic cancer immunotherapy resistance": 1,
    "Pancreatic cancer chemotherapy comparison": 1,
    "VRE infections": 1,
    "Biliary tract cancer chemo-immunotherapy": 1,
    "Cholangiocarcinoma FGFR resistance": 1,
    "Prostate cancer sequencing therapy": 1,
    "Resistant Gram-positive infections": 1,
    "AMR mechanisms in biofilms": 1,
    "Breast cancer CDK4/6 efficacy and safety": 1,
    "Prostate cancer resistance biomarkers": 1,
    "Resistant staphylococcal infections": 2,
    "Breast cancer CDK4/6 resistance": 1,
    "Viral-bacterial interactions and AMR": 1,
    "Lymphoma cellular therapy vs transplant": 1,
    "Breast cancer PI3K targeted therapy": 1,
    "AMR ecology": 1,
    "Alternative therapies for AMR": 1,
    "CAR T relapse mechanisms": 1,
    "Off-target assessment in HSC editing": 1,
    "CAR T predictors of response": 1,
    "AMR mechanisms": 2,
    "Prime vs base editing performance": 1,
    "Myeloma BCMA therapies comparison": 1,
    "Prime editing mechanisms and optimization": 1,
    "Myeloma biomarkers": 1,
    "PD-1/PD-L1 inhibitors in lung cancer": 1,
    "Checkpoint inhibitors and anti-angiogenic combinations": 1,
    "AML targeted combination therapy": 1,
    "Genome integrity in edited cell therapies": 1,
    "Antimicrobial dosing strategies": 1,
    "Checkpoint inhibitors in melanoma": 1,
    "AML BCL-2 resistance mechanisms": 1,
    "DNA damage response to editing": 1,
    "CML TKI discontinuation outcomes": 1,
    "Immunotherapy toxicity epidemiology": 2,
    "AMR diagnostics": 1,
    "Allogeneic CAR-T genome editing": 1,
    "Combination immunotherapy in renal cell carcinoma": 1,
    "Conditioning for HSC gene therapy": 1,
    "Checkpoint blockade in MSI-H/dMMR colorectal cancer": 1,
    "Innovations in conditioning regimens": 1,
    "Drug-resistant tuberculosis": 3,
    "Melanoma checkpoint regimen comparison": 1,
    "Insertional mutagenesis risk": 1,
    "Neoadjuvant immunotherapy in breast cancer": 1,
    "Vector design and expression control": 1,
    "Immunotherapy biomarkers (TMB)": 1,
    "Adjuvant checkpoint inhibitors": 1,
    "PD-1 inhibitors in head and neck cancer": 1,
    "Consolidation immunotherapy after chemoradiation": 1,
    "COVID-19 complications and AMR": 1,
    "Prognosis in neurogenetic gene therapy": 1,
    "Microbiome and immunotherapy outcomes": 1,
    "Microbiome mechanisms in immunotherapy": 1,
    "COVID-19 and AMR": 1,
    "Head and neck cancer immunotherapy": 1,
    "Gene therapy vs transplant in leukodystrophy": 1,
    "AMR stewardship strategies": 2,
    "HPV-related HNSCC biomarker": 1,
    "Immunodeficiency gene therapy outcomes": 1,
    "Checkpoint inhibitors in gynecologic cancers": 1,
    "Cervical cancer immunotherapy vs chemotherapy": 1,
    "Maintenance immunotherapy in urothelial cancer": 1,
    "Biomarker-stratified immunotherapy in GI cancers": 1,
    "Immune adverse events after gene therapy": 1,
    "Immunotherapy in prostate cancer": 1,
    "Cell therapy for neurodegeneration": 1,
    "Radio-immunotherapy resistance biology": 1,
    "AMR in neonatal infections": 1,
    "Glioblastoma chemotherapy biomarker": 1,
    "iPSC-RPE delivery formats": 1,
    "iPSC safety mechanisms": 1,
    "AMR screening": 1,
    "PD-1 blockade in lymphoma": 1,
    "Glioma chemotherapy resistance": 1,
    "Cardiac cell therapy comparisons": 1,
    "Glioma targeted therapy": 1,
    "Allogeneic iPSC immunology": 1,
    "CAR-T versus standard therapy in lymphoma": 1,
    "CAR-T safety in multiple myeloma": 1,
    "Multidrug-resistant Acinetobacter infections": 1,
    "Bladder cancer maintenance immunotherapy": 1,
    "CAR-T toxicity management": 1,
    "MSC mechanism of action": 1,
    "Sequencing immunotherapies in ALL": 1,
    "MSC therapy in GVHD": 1,
    "Prostate cancer intensification strategies": 1,
    "Biomarkers for cell therapy response": 1,
    "CAR-T in solid tumors and delivery strategies": 1,
    "AMR in surgical infections": 1,
    "Bladder cancer FGFR biomarkers": 1,
    "Regenerative therapies in OA": 1,
    "Mechanisms of checkpoint inhibitor resistance": 1,
    "AMR prognosis markers": 1,
    "Prostate cancer PARP biomarkers": 1,
    "CAR-T targets in glioblastoma": 1,
    "Breast cancer endocrine resistance": 1,
    "Safety epidemiology of MSC therapy": 1,
    "Antigen presentation and immune escape": 1,
    "Stem-cell derived beta cell therapy": 1,
    "AMR in immunocompromised hosts": 2,
    "Biomaterials in cell encapsulation": 1,
    "Colorectal cancer BRAF targeted therapy": 1,
    "TMB and neoantigen biology": 1,
    "Sarcoma immunotherapy efficacy by subtype": 1,
    "Anti-angiogenic resistance": 1,
    "IFN-γ pathway in immunotherapy response": 1,
    "CF gene therapy approaches": 1,
    "HIV and bacterial infections": 2,
    "DNA repair defects and immunotherapy": 1,
    "HIV and drug-resistant TB": 1,
    "Sarcoma immunotherapy biomarkers": 1,
    "Innate immunity and checkpoint response": 1,
    "Pulmonary CRISPR delivery": 1,
    "Cardiometabolic gene editing": 1,
    "CLL targeted therapy comparison": 1,
    "CLL BTK resistance mechanisms": 1,
    "Macrophages in the tumor microenvironment": 1,
    "HIV and COVID-19 outcomes": 2,
    "Ph+ ALL targeted therapy integration": 1,
    "LNP editing safety mechanisms": 1,
    "T-cell exclusion and stromal signaling": 1,
    "Mitochondrial gene therapy": 1,
    "ALL prognosis with MRD": 1,
    "Myeloid suppression mechanisms": 1,
    "HIV and COVID-19 immunology": 1,
    "Lymphoma immunotherapy disease-specific efficacy": 1,
    "Gene and cell therapy in neuro-oncology": 1,
    "Mitochondrial genome engineering": 1,
    "HIV prevention and STI control": 1,
    "Stromal biology and immunotherapy": 1,
    "Metabolic immunosuppression pathways": 1,
    "Hodgkin lymphoma immunotherapy mechanism": 1,
    "AMR in sexually transmitted infections": 1,
    "Hypoxia and immunotherapy resistance": 1,
    "Tregs and checkpoint therapy": 1,
    "AMR mechanisms in STIs": 1,
    "Gastric cancer HER2 therapy outcomes": 1,
    "Allogeneic vs autologous CAR-T": 1,
    "Resistance mechanisms in engineered cell therapy": 1,
    "COVID-19 and antimicrobial stewardship": 2,
    "COVID-19 and AMR epidemiology": 1,
    "Adverse events in engineered T-cell therapy": 1,
    "Gastric cancer HER2 resistance": 1,
    "NSCLC immunotherapy plus anti-angiogenic therapy": 1,
    "Immunotherapy outcomes modifiers": 1,
    "PD-L1 biology and biomarker interpretation": 1,
    "CAR-NK vs CAR-T safety/efficacy": 1,
    "Atypical responses to checkpoint inhibitors": 1,
    "Mechanisms of NK cell therapy safety": 1,
    "COVID-19 virology and immunology": 1,
    "Endometrial cancer immunotherapy combinations": 1,
    "CRISPR functional genomics in cancer": 1,
    "Microbiome perturbation and outcomes": 1,
    "Endometrial cancer biomarkers": 1,
    "Microbiome and immunotherapy mechanisms": 1,
    "CRISPR screening modalities": 1,
    "COVID-19 prognosis": 1,
    "Breast cancer brain metastases targeted therapy": 1,
    "Biosafety and shedding in gene therapy": 1,
    "CAR-T inflammatory toxicities": 1,
    "Targeted therapy CNS pharmacology": 1,
    "Concomitant medications and immunotherapy biology": 1,
    "Neuro-lysosomal gene therapy": 1,
    "CAR-T neurotoxicity mechanisms": 1,
    "NSCLC KRAS targeted therapy": 1,
    "NSCLC KRAS resistance mechanisms": 1,
    "CAR design and T-cell exhaustion": 1,
    "HIV/TB prevention": 1,
    "HIV vaccination": 2,
    "CNS gene therapy efficacy": 1,
    "CNS delivery mechanisms": 1,
    "Breast cancer mTOR targeted therapy": 1,
    "AMR in enteric infections": 2,
    "Prognosis in pediatric CNS gene therapy": 1,
    "Determinants of CAR-T persistence": 1,
    "Breast cancer endocrine resistance mechanisms": 1,
    "CAR-T relapse mechanisms": 1,
    "CAR-T target biology": 1,
    "AMR in gastrointestinal infections": 1,
    "CAR-T barriers in solid tumors": 1,
    "Genome editing in immunodeficiency": 1,
    "HIV and AMR colonization": 1,
    "NSCLC EGFR rechallenge strategies": 1,
    "Refractory colorectal cancer therapy comparison": 1,
    "Liquid biopsy for resistance monitoring": 1,
    "Engineered CAR-T trafficking strategies": 1,
    "Multi-target CAR-T engineering": 1,
    "HIV pathogenesis": 1,
    "HIV/TB diagnostics": 1,
    "CAR costimulatory domain biology": 1,
    "Ovarian cancer chemotherapy route comparison": 1,
    "Chemotherapy resistance transporters": 1,
    "HIV/TB immunopathology": 1,
    "Ovarian cancer prognosis and resistance": 1,
    "Chemo-immunotherapy mechanisms": 1,
    "Radiation-immunotherapy synergy": 1,
    "AMR drivers": 1,
    "Immune-related adverse events mechanisms": 1,
    "NSCLC chemotherapy regimen comparison": 1,
    "TNBC antibody-drug conjugate comparison": 1,
    "Anti-angiogenic immunomodulation": 1,
    "Immune-related adverse event epidemiology": 1,
    "Immune-related colitis biology": 1,
    "ADC resistance mechanisms": 1,
    "Chemotherapy response heterogeneity": 1,
    "Cross-disease": 8,
    "HIV and viral coinfections": 1,
    "Melanoma cellular therapy comparison": 1,
    "Risk factors for irAEs": 1,
    "COVID-19 vaccines in immunocompromised": 1,
    "Immune escape mechanisms": 1,
    "Endocrine irAE epidemiology": 1,
    "COVID-19 therapeutics in immunocompromised": 1,
    "Severe irAE incidence by regimen": 1,
    "RCC TKI comparison by risk group": 1,
    "CAR-T toxicity epidemiology": 1,
    "CAR-T neurotoxicity epidemiology": 1,
    "NSCLC immunotherapy outcomes by smoking status": 1,
    "RCC anti-angiogenic resistance mechanisms": 1,
    "HIV epidemiology": 1,
    "Immunotherapy response patterns": 1,
    "CAR-T hematologic toxicity": 1,
    "Autoimmunity after immunotherapy": 1,
    "Gastric cancer HER2 plus immunotherapy": 1,
    "Immunotherapy transcriptomic biomarkers": 1,
    "Age-related irAE epidemiology": 1,
    "HIV treatment initiation": 1,
    "MSI-H colorectal cancer first-line immunotherapy": 1,
    "Post-CAR-T infectious complications": 1,
    "AMR in respiratory infections": 1,
    "Atypical response patterns": 1,
    "Antibody therapeutics mechanism": 1,
    "Clinical predictors of immunotherapy response": 1,
    "Antibiotic optimization and AMR": 1,
    "DLBCL antibody-drug conjugate regimens": 1,
    "Lymphoma anti-CD20 resistance": 1,
    "AMR mechanisms and ecology": 1,
    "Breast cancer post-CDK4/6 endocrine options": 1,
    "Type 2 diabetes": 1,
    "Concomitant medications in immunotherapy cohorts": 1,
    "Breast cancer predictive biomarkers for SERDs": 1,
    "PD-L1 biomarker prevalence": 1,
    "Diabetes and obesity pharmacotherapy": 1,
    "Type 2 diabetes/CKD": 1,
    "NAFLD/NASH": 1,
    "Gastric cancer anti-angiogenic therapy": 1,
    "Taxane chemotherapy resistance": 1,
    "Predictive biomarkers in lung cancer": 1,
    "NAFLD with diabetes": 1,
    "Prognostic markers in melanoma immunotherapy": 1,
    "Inflammatory markers and outcomes": 1,
    "Late effects of chemotherapy": 1,
    "Obesity treatment": 1,
    "Genomic predictors of immunotherapy response": 1,
    "NSCLC chemoradiation and immunotherapy safety": 1,
    "Pediatric obesity": 1,
    "CML optimization strategies": 1,
    "Resistance predictors in MSI-H cancers": 1,
    "Hyperprogression epidemiology": 1,
    "Type 2 diabetes pharmacotherapy": 1,
    "CML resistance biomarkers": 1,
    "irAEs as outcome correlates": 1,
    "NSCLC MET targeted therapy": 1,
    "Type 1 diabetes technology": 2,
    "Inpatient diabetes management": 1,
    "Clinical risk models in immunotherapy": 1,
    "NSCLC MET resistance": 1,
    "Oncogenic drivers and immunotherapy outcomes": 1,
    "Metabolic syndrome": 1,
    "Genomic resistance markers in lung cancer": 1,
    "Tumor-agnostic TRK inhibition outcomes": 1,
    "NSCLC RET targeted therapy comparison": 1,
    "NAFLD lifestyle": 1,
    "Immunotherapy outcomes in CNS disease": 1,
    "NSCLC HER2-targeted ADC": 1,
    "Obesity and comorbidity": 1,
    "Colorectal cancer HER2 targeted therapy": 1,
    "CAR-T predictors of toxicity and efficacy": 1,
    "ADC pulmonary toxicity mechanisms": 1,
    "NAFLD/NASH and diabetes": 1,
    "Type 2 diabetes insulin": 1,
    "Sequencing BCMA-targeted therapies": 1,
    "CAR-T pharmacodynamics and outcomes": 1,
    "Obesity nutrition": 2,
    "Tumor microenvironment biomarkers": 1,
    "Colorectal cancer prognostic biomarkers": 1,
    "Liquid biopsy monitoring in immunotherapy": 1,
    "TNBC immunotherapy biomarker effect": 1,
    "Gestational diabetes": 1,
    "Virus-associated tumor immunotherapy outcomes": 1,
    "NAFLD diagnostics": 1,
    "PD-L1 assay harmonization": 1,
    "Transcriptomic predictors of immunotherapy": 1,
    "Virus status and checkpoint response": 1,
    "Prediabetes prevention": 1,
    "Ovarian cancer platinum resistance mechanisms": 1,
    "Colorectal cancer predictive clinical factors": 1,
    "NSCLC first-line regimen selection by PD-L1": 1,
    "NAFLD mechanisms": 1,
    "Obesity mechanisms": 2,
    "Immunotherapy in special populations": 1,
    "Obesity and microbiome": 1,
    "Systemic inflammation biomarkers in immunotherapy": 1,
    "Checkpoint inhibitors in transplant recipients": 1,
    "NAFLD/NASH mechanisms": 1,
    "Checkpoint inhibitor class comparisons": 1,
    "Metastatic site impact on immunotherapy outcomes": 1,
    "Diabetes drug mechanisms": 2,
    "NSCLC immunotherapy beyond progression": 1,
    "Radiotherapy-immunotherapy synergy": 1,
    "Obesity pharmacology": 1,
    "Triplet immunotherapy regimens in lung cancer": 1,
    "Frontline immunotherapy in ovarian cancer": 1,
    "Immunotherapy combinations in MSS colorectal cancer": 1,
    "Metabolic endocrine signaling": 1,
    "HER2 therapy cardiotoxicity epidemiology": 1,
    "Immunotherapy in small cell lung cancer": 1,
    "Type 2 diabetes pathophysiology": 1,
    "Colorectal cancer chemotherapy intensification": 1,
    "Checkpoint blockade in skin cancers": 1,
    "Diabetes complications mechanisms": 1,
    "Chemotherapy toxicity mechanisms": 1,
    "Pharmacogenomics of chemotherapy": 1,
    "Combination strategies in endometrial cancer": 1,
    "Insulin resistance mechanisms": 1,
    "Checkpoint inhibitors in biliary tract cancer": 1,
    "Immunotherapy in virus-associated head and neck cancers": 1,
    "NSCLC HER3 ADC after EGFR therapy": 1,
    "Metabolic lipid signaling": 1,
    "Obesity risk mechanisms": 1,
    "NSCLC EGFR resistance via transformation": 1,
    "Cellular therapy versus bispecifics in lymphoma": 1,
    "Multi-antigen CAR-T strategies": 1,
    "Chemotherapy neuropathy epidemiology": 1,
    "Prognostic lab biomarkers in immunotherapy": 1,
    "NAFLD dietary mechanisms": 1,
    "Colorectal cancer ctDNA-guided rechallenge": 1,
    "Lymphodepletion optimization for CAR-T": 1,
    "Circulating biomarkers in immunotherapy": 1,
    "NASH fibrosis mechanisms": 1,
    "Evolutionary mechanisms of resistance": 1,
    "NAFLD signaling": 1,
    "Site-specific metastases and immunotherapy outcomes": 1,
    "Microbiome as predictive biomarker": 1,
    "Immunotherapy rechallenge safety": 1,
    "TCR repertoire biomarkers": 1,
    "Obesity neuroendocrinology": 1,
    "Body composition and immunotherapy outcomes": 1,
    "NAFLD adipokines": 1,
    "Supportive care with intensive chemotherapy": 1,
    "Chemotherapy dose intensity and outcomes": 1,
    "Colorectal cancer anti-VEGF benefit by age": 1,
    "Long-term immune consequences of CAR-T": 1,
    "Geriatric oncology chemotherapy toxicity prediction": 1,
    "NAFLD epidemiology": 1,
    "Biomarkers of CAR-T toxicity": 1,
    "NSCLC brain metastases combined therapy": 1,
    "Exercise and metabolism": 1,
    "Prediabetes epidemiology": 1,
    "PD-L1 testing methodology": 1,
    "Obesity epidemiology": 2,
    "Diabetes risk epidemiology": 3,
    "Pan-cancer biomarkers": 1,
    "Microbiome and immunotherapy toxicity": 1,
    "NAFLD risk epidemiology": 3,
    "HER2 ADC comparative outcomes": 1,
    "Heart Failure": 52,
    "Genomic biomarkers of response": 1,
    "NSCLC platinum resistance mechanisms": 1,
    "Melanoma immunotherapy long-term outcomes": 1,
    "Treatment duration and de-escalation": 1,
    "Immunotherapy mechanism (T-cell repertoire)": 1,
    "NAFLD phenotypes": 1,
    "Immunotherapy rechallenge": 1,
    "Coronary Artery Disease": 57,
    "Environmental metabolic epidemiology": 1,
    "Management of irAEs": 1,
    "Youth diabetes epidemiology": 1,
    "Gestational diabetes outcomes": 1,
    "Site-specific immunotherapy outcomes": 1,
    "Microbiome interventions in immunotherapy": 1,
    "NAFLD comorbidity epidemiology": 1,
    "Combination immunotherapy with DNA repair targeting": 1,
    "Next-generation checkpoint combinations": 1,
    "Checkpoint inhibitors in immunocompromised or chronically infected patients": 1,
    "SCLC chemo-immunotherapy": 1,
    "SCLC resistance mechanisms": 1,
    "NAFLD complications epidemiology": 1,
    "CRISPR vs gene addition therapies": 1,
    "Preventing CAR-T relapse": 1,
    "Combination cellular therapy and checkpoint inhibitors": 1,
    "HSC gene therapy durability": 1,
    "Allogeneic versus autologous CAR-T": 1,
    "Gene regulation mechanisms in editing": 1,
    "Imaging biomarkers for immunotherapy": 1,
    "Spatial immuno-oncology biomarkers": 1,
    "In vivo CRISPR delivery": 1,
    "NAFLD disparities": 1,
    "Obesity and pregnancy epidemiology": 1,
    "Composite biomarker stratification in lung cancer": 1,
    "NAFLD detection epidemiology": 1,
    "Oncolytic virus combinations": 1,
    "Immunogenicity of CRISPR components": 1,
    "Genome editing precision": 1,
    "TILs as predictive biomarkers": 1,
    "Atrial Fibrillation": 52,
    "Prediabetes prognosis": 1,
    "NAFLD outcomes epidemiology": 1,
    "Base editing mechanisms": 1,
    "Treatment history effects on immunotherapy outcomes": 1,
    "Ocular gene therapy vs editing": 1,
    "Diabetes prognosis/monitoring": 1,
    "Bridging therapy in CAR-T pathways": 1,
    "NAFLD prognosis": 1,
    "Host genetics and immunotherapy outcomes": 1,
    "AAV safety and persistence": 1,
    "Diabetes complications prognosis": 3,
    "Transgene expression durability": 1,
    "Hemophilia gene therapy strategies": 1,
    "Gene therapy vs RNA therapy outcomes": 1,
    "Host factors and immunotherapy outcomes": 1,
    "Gestational diabetes prognosis": 1,
    "Prognostic factors in gene replacement": 1,
    "Diabetes remission": 1,
    "Neoantigen clonality and response": 1,
    "NAFLD progression": 1,
    "Vector tropism in muscle gene therapy": 1,
    "Obesity life-course prognosis": 1,
    "Peripheral blood biomarkers": 1,
    "Mutational signatures and immunotherapy": 1,
    "Tumor microenvironment structures and response": 1,
    "DMD therapeutic comparisons": 1,
    "Type 1 diabetes prognosis": 1,
    "B-cell immunity in the tumor microenvironment": 1,
    "NAFLD prognosis/diagnostics": 1,
    "Histologic subtype differences in immunotherapy": 1,
    "AAV-associated toxicities": 1,
    "Type 2 diabetes long-term outcomes": 1,
    "Systemic AAV adverse events": 1,
    "Obesity prognosis": 1,
    "Seroprevalence and trial eligibility": 1,
    "Treatment sequencing after resistance": 1,
    "Gene editing vs gene silencing": 1,
    "Time course of endocrine irAEs": 1,
    "Cutaneous irAEs and efficacy correlations": 1,
    "NAFLD prognosis/treatment response": 1,
    "Long-term follow-up in pediatric gene therapy": 1,
    "Germline vs somatic editing mechanisms": 1,
    "NAFLD prognosis/biomarkers": 1,
    "Administration-related adverse events": 1,
    "Long-term safety of CAR-T": 1,
    "Type 2 diabetes treatment": 1,
    "Clinical trial epidemiology of iPSC therapies": 1,
    "Checkpoint inhibitors in CNS metastatic disease": 1,
    "Cell sources for cartilage regeneration": 1,
    "Mechanisms in cartilage tissue engineering": 1,
    "NASH pharmacotherapy": 1,
    "Intracranial efficacy in lung cancer": 1,
    "Cell therapy for liver failure": 1,
    "NAFLD supplements": 1,
    "Obesity pharmacotherapy": 2,
    "Diabetes lifestyle therapy": 1,
    "Combination immunotherapy for melanoma brain metastases": 1,
    "Prognosis in hepatocyte cell therapy": 1,
    "CAR-T logistics and outcomes": 1,
    "Engineered myeloid cell therapies": 1,
    "PET biomarkers in immunotherapy": 1,
    "NAFLD interventions": 1,
    "Diabetes treatment adherence": 1,
    "Imaging response assessment in immunotherapy": 1,
    "Macrophage engineering mechanisms": 1,
    "Stem cell therapy in ocular surface disease": 1,
    "Alternative immune checkpoints and resistance": 1,
    "Ectopic tissue risk in cell therapy": 1,
    "Type 2 diabetes medication optimization": 1,
    "Checkpoint combination regimens": 1,
    "Diabetes nutrition": 1,
    "NAFLD and obesity treatment": 1,
    "Emerging checkpoint combinations in lung cancer": 1,
    "Innate immune cells in resistance": 1,
    "Correction vs splice modulation": 1,
    "Therapeutic mechanism selection": 1,
    "NAFLD lifestyle epidemiology": 1,
    "Neurotoxicity mechanisms in AAV": 1,
    "Tumor metabolism and immune suppression": 1,
    "Immunometabolism in the tumor microenvironment": 1,
    "CNS gene silencing strategies": 1,
    "NAFLD pharmacoepidemiology": 1,
    "Tumor immune phenotypes": 1,
    "Gene therapy in lysosomal disorders": 1,
    "Renal prognosis in gene-modified Fabry": 1,
    "Diabetes medication safety": 1,
    "Liquid biopsy prognostic stratification": 1,
    "Dual-AAV mechanistic optimization": 1,
    "Renal irAEs and outcomes": 1,
    "Strategies for large transgenes": 1,
    "NAFLD cardiovascular epidemiology": 1,
    "Predicting toxicity in immunotherapy": 1,
    "Tumor immune evasion genomics": 1,
    "Promoter selection in ocular gene therapy": 1,
    "Diabetes complications epidemiology": 1,
    "Long-term safety epidemiology": 1,
    "CAR-T biomarkers in myeloma": 1,
    "Diabetes prevention epidemiology": 1,
    "Prior therapies influencing CAR-T outcomes": 1,
    "Gestational diabetes epidemiology": 1,
    "Manufacturing and clinical outcomes": 1,
    "Safe-harbor editing vs gene transfer": 1,
    "NAFLD genetics": 1,
    "Safe-harbor locus mechanisms": 1,
    "Extracellular vesicles and immune suppression": 1,
    "Epigenetics and immunotherapy sensitivity": 1,
    "Diabetes supplements": 1,
    "NAFLD microbiome interventions": 1,
    "Comparative predictive biomarkers": 1,
    "Refractory irAE patterns": 1,
    "Procedure-related ocular safety": 1,
    "In vivo vs ex vivo ocular gene approaches": 1,
    "Cell therapy for spinal cord injury": 1,
    "Neural cell graft integration mechanisms": 1,
    "Antibiotics and immunotherapy outcomes": 1,
    "NASH diagnostics": 1,
    "Type 2 diabetes remission": 1,
    "Obesity/diabetes drug safety": 1,
    "Tumor microbiome and immunotherapy": 1,
    "Concomitant medications affecting immunotherapy": 1,
    "Vascular regenerative cell therapy": 1,
    "Bariatric surgery outcomes": 1,
    "Prognosis in vascular cell therapy": 1,
    "Systemic immune profiling biomarkers": 1,
    "Type 2 diabetes technology": 1,
    "Cross-resistance and sequencing in melanoma": 1,
    "NASH clinical trial endpoints": 1,
    "Real-world prognostic factors": 1,
    "RNA editing mechanisms": 1,
    "Sex as a modifier of immunotherapy outcomes": 1,
    "RNA-targeting gene therapies": 1,
    "NAFLD pharmacotherapy": 2,
    "Metabolic chronobiology": 1,
    "Comparative predictors in melanoma": 1,
    "Type 2 diabetes combination therapy": 1,
    "Peripheral immune monitoring": 1,
    "Diabetes and heart failure": 1,
    "NAFLD lifestyle intervention": 1,
    "Type 2 diabetes treatment strategy": 1,
    "NAFLD outcomes": 1,
    "Diabetes medication tolerability": 1,
    "Obesity treatment response": 1,
    "NAFLD biomarkers": 1,
    "Diabetes prognosis": 1,
    "NAFLD comorbidity prognosis": 1,
    "Diabetes therapy and NAFLD": 1,
    "Drug development/Phase III trials (Hepatology)": 1,
    "Obesity lifestyle": 1,
    "Drug development/Phase III trials (Gastroenterology)": 3,
    "Genome integrity and QC": 1,
    "Liver genetic disease interventions": 1,
    "Sensory gene therapy": 1,
    "Disease mechanism targeted by editing": 1,
    "Drug development/Phase III trials (Pain/NSAIDs)": 1,
    "Inner ear delivery optimization": 1,
    "Drug development/Phase III trials (Perioperative medicine/Anticoagulation)": 1,
    "Ex vivo corrected stem cell grafts": 1,
    "Gene editing for HIV": 1,
    "Engraftment prognosis in skin gene therapy": 1,
    "Drug interactions/Clinical pharmacology (HIV/Cardiology)": 1,
    "Targeting latent reservoirs": 1,
    "Drug interactions/Clinical pharmacology (Cardiology)": 4,
    "Drug interactions/Clinical pharmacology (Cardiology/Psychiatry)": 2,
    "Gene-based therapy in rare disease": 1,
    "Transgene design considerations": 1,
    "Immunogenicity of expressed transgenes": 1,
    "Gene therapy for metabolic myopathy": 1,
    "Drug interactions/Clinical pharmacology (Cardiology/Urology)": 1,
    "Re-dosing and immune barriers": 1,
    "Drug interactions/Clinical pharmacology (Infectious disease/Women's health)": 1,
    "Muscle transduction mechanisms": 1,
    "Management strategies in gene therapy": 1,
    "Drug interactions/Clinical pharmacology (Infectious disease/Nephrology)": 1,
    "Drug interactions/Clinical pharmacology (Endocrinology/Radiology)": 1,
    "CRISPR system biochemistry and safety": 1,
    "Editor platform comparisons": 1,
    "Cardiac amyloidosis gene therapy comparison": 1,
    "Clinical trials/Prognostic modifiers (Oncology/Immunotherapy)": 1,
    "Novel delivery systems": 1,
    "Intracellular delivery mechanisms": 1,
    "Clinical trials/Prognostic modifiers (Oncology/Immunotherapy, drug interaction-like)": 1,
    "LNP infusion safety": 1,
    "Clinical trials/Prognosis (Cardiology/Hematology)": 1,
    "Clinical trials/Prognosis (Nephrology/Diabetes)": 1,
    "Safety epidemiology in autoimmune CAR-T": 1,
    "Clinical trials/Prognostic biomarkers (Pulmonology)": 1,
    "Clinical trials/Prognostic biomarkers (Pulmonology/Immunology)": 1,
    "Engineered cell therapy in autoimmunity": 1,
    "Clinical trials/Prognostic biomarkers (Oncology)": 1,
    "Clinical trials/Prognostic biomarkers (Oncology/Immunotherapy)": 1,
    "Mechanisms of CAR-T long-term effects": 1,
    "Predictors of MSC response in IBD": 1,
    "Stem cell therapies in IBD": 1,
    "Clinical trials/Prognosis (Oncology/Breast)": 1,
    "Clinical trials/Safety epidemiology (Immunology/Rheumatology)": 1,
    "Clinical trials/Safety (Endocrinology)": 1,
    "Ocular gene therapy for complement pathway": 1,
    "Engineered immune cell therapy": 1,
    "Treg engineering mechanisms": 1,
    "Clinical trials/Safety epidemiology (Dermatology/Immunology)": 1,
    "Clinical trials/Safety epidemiology (Oncology)": 2,
    "Ocular gene therapy safety epidemiology": 1,
    "Epigenome editing therapeutics": 1,
    "Epigenetic editing mechanisms": 1,
    "Clinical trials/Safety epidemiology (Hematology/Oncology)": 1,
    "Clinical trials/Safety epidemiology (Endocrinology)": 1,
    "MSC therapy in critical care": 1,
    "Drug interactions within trials (Cardiology/Hematology)": 1,
    "MSC systemic safety": 1,
    "Clinical trials/Safety epidemiology (Cardiology/Metabolic)": 1,
    "Universal donor iPSC engineering": 1,
    "Clinical trial methodology (PROs)": 1,
    "Clinical trials/Safety epidemiology (Oncology/Cardio-oncology)": 1,
    "Immune evasion engineering mechanisms": 1,
    "CNS-targeted gene therapy in MPS": 1,
    "Prognosis in CNS lysosomal gene therapy": 1,
    "Clinical trial methodology (Noninferiority)": 1,
    "Clinical trial methodology (Oncology endpoints)": 1,
    "Vector persistence biology": 1,
    "Clinical trial methodology (Cardiology endpoints)": 1,
    "HSC editing methods": 1,
    "Non-integrating vector strategies": 1,
    "Drug development/Clinical trials (Pharmacogenomics/Antiplatelets)": 1,
    "Drug development/Clinical trials (Pharmacogenomics)": 1,
    "Drug development/Phase III trials (Oncology/Melanoma)": 1,
    "Enhancing precise editing": 1,
    "HDR safety considerations": 1,
    "NAFLD pharmacogenomics": 1,
    "NAFLD cancer mechanisms": 1,
    "DNA repair pathway control": 1,
    "Type 2 diabetes mechanisms": 1,
    "Obesity adipose biology": 1,
    "Drug development/Phase III trials (Oncology/Prostate)": 3,
    "Type 2 diabetes incretin biology": 1,
    "Drug development/Phase III trials (Oncology/Liver)": 1,
    "Drug development/Phase III trials (Oncology/Kidney)": 1,
    "Metabolomics and diabetes": 1,
    "Type 2 diabetes inflammation": 1,
    "Type 2 diabetes immunometabolism": 1,
    "Sex differences in metabolic disease": 1,
    "Metabolic measurement methods": 1,
    "Drug development/Phase III trials (Oncology/Gynecology)": 2,
    "Integrated cardiometabolic management": 1,
    "NAFLD procedural therapies": 1,
    "Type 2 diabetes glycemic patterns": 1,
    "Drug development/Phase III trials (Neuro-oncology)": 1,
    "Obesity pharmacotherapy outcomes": 1,
    "Drug development/Phase III trials (Neurology/MS)": 1,
    "Drug development/Phase III trials (Neurology/Headache)": 2,
    "Drug development/Phase III trials (Neurology/Neurodegeneration)": 1,
    "NASH biomarkers": 1,
    "Drug development/Phase III trials (Neurology/Stroke)": 1,
    "NAFLD natural history": 1,
    "Drug development/Phase III trials (Psychiatry)": 3,
    "Obesity behavioral intervention": 1,
    "Diabetes renal outcomes": 1,
    "Drug development/Phase III trials (Infectious disease/HIV)": 1,
    "Diabetes care delivery": 1,
    "Obesity phenotypes": 1,
    "Drug development/Phase III trials (Thrombosis)": 1,
    "NAFLD lifestyle risk": 1,
    "Type 2 diabetes remission strategies": 1,
    "Drug development/Phase III trials (Infectious disease/Pediatrics)": 1,
    "Drug development/Phase III trials (Diabetes)": 1,
    "Drug development/Phase III trials (Cardiology/Anticoagulation)": 1,
    "Developmental timing in gene therapy": 1,
    "Drug development/Phase III trials (Infectious disease/TB)": 1,
    "Drug development/Phase III trials (Infectious disease/Antibiotics)": 1,
    "Drug development/Phase III trials (Diabetes/Cardiovascular outcomes)": 1,
    "Drug development/Phase III trials (Endocrinology/Bone)": 1,
    "Drug development/Phase III trials (Obesity)": 1,
    "Drug development/Phase III trials (Nephrology/Hematology)": 1,
    "Drug development/Phase III trials (Heart failure)": 1,
    "Drug development/Phase III trials (Nephrology)": 1,
    "Drug development/Phase III trials (Rheumatology/Metabolic)": 1,
    "Drug development/Phase III trials (Urology)": 2,
    "Drug development/Phase III trials (Cardiovascular prevention)": 1,
    "Drug development/Phase III trials (Hypertension)": 1,
    "Drug development/Phase III trials (Gynecology)": 1,
    "Drug development/Phase III trials (Dermatology)": 1,
    "Drug development/Phase III trials (Dermatology/Immunology)": 1,
    "Drug development/Phase III trials (Obstetrics)": 1,
    "Drug development/Phase III trials (Anesthesiology/Pain)": 1,
    "Drug development/Phase III trials (Gastroenterology/IBD)": 2,
    "Drug development/Phase III trials (Supportive oncology)": 1,
    "Drug development/Phase III trials (Allergy/Immunology)": 1,
    "Drug development/Phase III trials (Hematology)": 3,
    "Drug development/Phase III trials (Rheumatology/Dermatology)": 1,
    "Drug development/Phase III trials (Neuromuscular/Rare disease)": 1,
    "Drug development/Phase III trials (Neurology/Rare disease)": 1,
    "Drug development/Phase III trials (Pulmonology)": 1,
    "Drug development/Phase III trials (Pulmonology/COPD)": 1,
    "Drug development/Phase III trials (Pulmonary vascular disease)": 1,
    "Drug development/Phase III trials (Addiction medicine)": 2,
    "COVID-19 immunomodulators": 1
  },
  "question_types": {
    "prognosis": 302,
    "epidemiology": 203,
    "mechanism": 285,
    "efficacy_comparison": 610,
    "review": 119
  },
  "avg_tool_calls": 1.4805793285055957,
  "generation_time": "2025-12-17T05:43:34.470658",
  "has_rubrics": false
}